What’s new

• Rahul Adakmol appointed CEO effective 15 July 2026, replacing Narsimha Kamath.
• Kamath steps down as CEO but remains managing director.
• Santosh Parab, former independent director, appointed additional non-executive non-independent director.

Why it matters

This CEO change is the first visible management shift after Anupam Rasayan's 43.3% stake buy. With a new promoter and a new CEO from a large-pharma background, the company is signalling a strategic pivot. Kamath's continued presence as MD provides some continuity, but the real test is whether Adakmol's appointment aligns operational priorities with the incoming promoter's vision.

What we’re watching

• Any strategic shifts or restructuring under Adakmol's leadership.
• Integration with Anupam Rasayan's business and potential combined operations.
• Kamath's role as MD and whether he remains involved in day-to-day operations.

The full read

Bliss GVS Pharma is getting a new CEO, and the timing is no coincidence. The board appointed Rahul Adakmol to take charge from 15 July 2026, replacing Narsimha Kamath who steps down as CEO but stays on as managing director. Adakmol brings a pedigree from Dr. Reddy's, Bharat Serums, and Reliance — experience that fits a company now under the control of Anupam Rasayan, which bought a 43.3% stake last year. The two-year runway before the switch gives Kamath room to hand over smoothly, and his continued presence as MD offers some stability. But the message is clear: the new promoter wants its own leadership in place. For a mid-cap pharma with ₹5,217 crore market cap and trailing PAT growth of 122%, the next strategic direction will be closely watched. The open question is what strategic priorities Adakmol will pursue once in the driver's seat.

Primary source: BSE · NSE